226 related articles for article (PubMed ID: 31173157)
1. Zoledronic acid inhibits osteoclast differentiation and function through the regulation of NF-κB and JNK signalling pathways.
Huang XL; Huang LY; Cheng YT; Li F; Zhou Q; Wu C; Shi QH; Guan ZZ; Liao J; Hong W
Int J Mol Med; 2019 Aug; 44(2):582-592. PubMed ID: 31173157
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid inhibits osteoclastogenesis and bone resorptive function by suppressing RANKL‑mediated NF‑κB and JNK and their downstream signalling pathways.
Huang XL; Liu C; Shi XM; Cheng YT; Zhou Q; Li JP; Liao J
Mol Med Rep; 2022 Feb; 25(2):. PubMed ID: 34935053
[TBL] [Abstract][Full Text] [Related]
3. Shikimic Acid Inhibits Osteoclastogenesis in Vivo and in Vitro by Blocking RANK/TRAF6 Association and Suppressing NF-κB and MAPK Signaling Pathways.
Chen X; Li X; Zhai X; Zhi X; Cao L; Qin L; Su J
Cell Physiol Biochem; 2018; 51(6):2858-2871. PubMed ID: 30562759
[TBL] [Abstract][Full Text] [Related]
4. Administration of zoledronic acid alleviates osteoporosis in HIV patients by suppressing osteoclastogenesis via regulating RANKL expression.
Lin W; Li XF; Ren DC; Song M; Duan L; Liu JZ; Zhan ZR
Mol Med; 2021 Feb; 27(1):19. PubMed ID: 33637048
[TBL] [Abstract][Full Text] [Related]
5. Glycyrrhizic acid suppresses osteoclast differentiation and postmenopausal osteoporosis by modulating the NF-κB, ERK, and JNK signaling pathways.
Yin Z; Zhu W; Wu Q; Zhang Q; Guo S; Liu T; Li S; Chen X; Peng D; Ouyang Z
Eur J Pharmacol; 2019 Sep; 859():172550. PubMed ID: 31323222
[TBL] [Abstract][Full Text] [Related]
6. Palmitoleic Acid Inhibits RANKL-Induced Osteoclastogenesis and Bone Resorption by Suppressing NF-κB and MAPK Signalling Pathways.
van Heerden B; Kasonga A; Kruger MC; Coetzee M
Nutrients; 2017 Apr; 9(5):. PubMed ID: 28452958
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of zoledronic acid derivatives with extended methylene linkers on osteoclastogenesis involve downregulation of JNK and Akt pathways.
Peng Y; Liu Q; Xu D; Li K; Li H; Qiu L; Lin J
Cell Biol Int; 2021 May; 45(5):1015-1029. PubMed ID: 33404170
[TBL] [Abstract][Full Text] [Related]
8. Bergapten suppresses RANKL-induced osteoclastogenesis and ovariectomy-induced osteoporosis via suppression of NF-κB and JNK signaling pathways.
Chen G; Xu Q; Dai M; Liu X
Biochem Biophys Res Commun; 2019 Feb; 509(2):329-334. PubMed ID: 30579598
[TBL] [Abstract][Full Text] [Related]
9. Desoxyrhapontigenin inhibits RANKL‑induced osteoclast formation and prevents inflammation‑mediated bone loss.
Tran PT; Park DH; Kim O; Kwon SH; Min BS; Lee JH
Int J Mol Med; 2018 Jul; 42(1):569-578. PubMed ID: 29693149
[TBL] [Abstract][Full Text] [Related]
10. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
11. NF-κB pathway inhibition by anthrocyclic glycoside aloin is key event in preventing osteoclastogenesis in RAW264.7 cells.
Pengjam Y; Madhyastha H; Madhyastha R; Yamaguchi Y; Nakajima Y; Maruyama M
Phytomedicine; 2016 Apr; 23(4):417-28. PubMed ID: 27002412
[TBL] [Abstract][Full Text] [Related]
12. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
[TBL] [Abstract][Full Text] [Related]
13. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
[TBL] [Abstract][Full Text] [Related]
14. Amiloride inhibits osteoclastogenesis by suppressing nuclear factor-κB and mitogen-activated protein kinase activity in receptor activator of nuclear factor-κB-induced RAW264.7 cells.
Wang X; Zhu Y; Zheng S; Ni C; Zhao L; Liu C; Chen A; Xiao J
Mol Med Rep; 2015 May; 11(5):3451-6. PubMed ID: 25592168
[TBL] [Abstract][Full Text] [Related]
15.
Chen Y; Wei B; Xu P; Tang H; Yang L; Wang Y; Fu Y; Yang X; Mao Y
Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 33576450
[TBL] [Abstract][Full Text] [Related]
16. Crocin inhibits RANKL‑induced osteoclastogenesis by regulating JNK and NF‑κB signaling pathways.
Shi L; Zhao S; Chen Q; Wu Y; Zhang J; Li N
Mol Med Rep; 2018 Jun; 17(6):7947-7951. PubMed ID: 29620194
[TBL] [Abstract][Full Text] [Related]
17. Carnosol inhibits osteoclastogenesis
Cai P; Yan S; Lu Y; Zhou X; Wang X; Wang M; Yin Z
Mol Med Rep; 2022 Jul; 26(1):. PubMed ID: 35593299
[TBL] [Abstract][Full Text] [Related]
18. Zoledronate and high glucose levels influence osteoclast differentiation and bone absorption via the AMPK pathway.
Dong W; Qi M; Wang Y; Feng X; Liu H
Biochem Biophys Res Commun; 2018 Nov; 505(4):1195-1202. PubMed ID: 30322621
[TBL] [Abstract][Full Text] [Related]
19. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
20. Aspirin inhibits osteoclastogenesis by suppressing the activation of NF-κB and MAPKs in RANKL-induced RAW264.7 cells.
Zeng YP; Yang C; Li Y; Fan Y; Yang HJ; Liu B; Sang HX
Mol Med Rep; 2016 Sep; 14(3):1957-62. PubMed ID: 27430169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
